Overview

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

Status:
Completed
Trial end date:
2011-06-21
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may help gemcitabine work better by making cancer cells more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving bortezomib together with gemcitabine works in treating patients with relapsed mantle cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Treatments:
Bortezomib
Gemcitabine